Furrukh Jabbar, MD
Surgical Oncology · Plano, TXNPI 1104067552
Payments from drug & device makers
What this record shows
This record is dominated by education: $3,000 of the $4,213 with a category attached, or 71.2%. Intuitive Surgical accounts for 71.2% of it on its own, with 19 other manufacturers making up the rest. Reporting peaked in 2019 at $3,052 and has fallen 94.1% since, to $180 in 2025.
Across 38 payments — averaging $110.88 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Intuitive Surgical$3K
- Lexington Medical, Inc.$159
- TELA Bio, Inc.$151
- Davol Inc.$142
- Angiodynamics, Inc.$128
- Boston Scientific$106
- plus $528 from 14 others
What the payments were for
- Food & beverage$1,21329%
- Education$3,00071%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Intuitive Surgical | 1 | $3,000 |
| Lexington Medical, Inc. | 1 | $159 |
| TELA Bio, Inc. | 4 | $151 |
| Davol Inc. | 5 | $142 |
| Angiodynamics, Inc. | 1 | $128 |
| Boston Scientific | 1 | $106 |
| Integra Lifesciences Corporation | 6 | $95 |
| Johnson & Johnson | 3 | $75 |
| Smith+Nephew | 2 | $56 |
| Access Pro Medical, LLC | 1 | $45 |
| Medtronic | 3 | $44 |
| Perspectum Diagnostics Ltd | 1 | $39 |
| Tactile Systems Technology Inc | 2 | $34 |
| Baxter Healthcare | 1 | $30 |
| BD | 1 | $24 |
| Acera Surgical, Inc. | 1 | $22 |
| Avanos Medical | 1 | $20 |
| Bard Peripheral Vascular, Inc. | 1 | $15 |
| Solventum Corporation | 1 | $15 |
| Pacira Pharmaceuticals Incorporated | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$4,213 in reported general payments places this provider in the 70th percentile of 191 surgical oncology providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 12 | $125 |
| Neomycin Sulfate | 21 | $108 |
| Metronidazole | 22 | $47 |
| Sulfamethoxazole-TrimethoprimSulfamethoxazole/Trimethoprim | 14 | $41 |
Paid to pharmacies, not to this prescriber.
Other surgical oncology in Plano
- Lynn CanavanPlano$11K
- Muhammad ButtPlano$7K
- Allison DipasqualeDallas$272K
- Merrick RossHouston$216K
- John HardawayShenandoah$164K
- Steven CurleyTyler$162K
- Suhail SharifFort Worth$137K
- Alfredo Santillan GomezSan Antonio$125K
- Kelly HuntHouston$104K
- Adam YoppDallas$96K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.